BioWorld Asia

March 8, 2006

NicOx Shares Soar On Pfizer Deal For Ophthalmic Drugs

The French firm NicOx SA stands to break the bank, to the tune of up to nearly $400 million, per terms of a technology deal with Pfizer Inc. (BioWorld International) Read More

Basilea Shares Hit Peak On Positive Ceftobiprole Data

Antisense RNA Therapy Shows Promise In Muscular Dystrophy

GTC Biotherapeutics’ ATryn Gets Negative Vote In Europe

Positive Results For ATL-104 Have Alizyme Thinking Ahead

Diabetica To Receive Up To $41M Through Amylin Deal

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 16, 2026.

AI-generated illustration of a neuron with tau protein aggregation

AAIC 2026: Age of amyloid is being joined by time of tau

BioWorld

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Voyager’s gene therapy reduces tau levels in AD models

BioWorld Science

At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...